DMT (N,N-Dimethyltryptamine)
A potent endogenous psychedelic found in hundreds of plant species and produced in the mammalian brain — at the center of questions about consciousness, entity encounters, and the boundary between neuroscience and the numinous.
About DMT (N,N-Dimethyltryptamine)
N,N-Dimethyltryptamine (DMT) is a simple indole alkaloid — two methyl groups attached to the amino nitrogen of tryptamine — that produces what is widely described as the most intense and reality-altering psychedelic experience known. Its molecular structure is nearly identical to serotonin (5-hydroxytryptamine), differing by only a hydroxyl group and two methyl groups, and it belongs to the same tryptamine family as psilocin, melatonin, and bufotenine. This structural kinship with the brain's primary modulatory neurotransmitter is part of what makes DMT so scientifically significant: it suggests that the most powerful known consciousness-altering compound is not an exotic foreign molecule but a close relative of the chemistry already running in every human brain.
DMT is found in hundreds of plant species across dozens of botanical families — a distribution so wide that ethnobotanist Jonathan Ott has described it as 'the most widespread psychoactive compound in nature.' Notable sources include Psychotria viridis (chacruna, used in ayahuasca), Mimosa tenuiflora (jurema, used in South American snuffs and brews), Anadenanthera peregrina (yopo, the source of traditional Amazonian snuffs), Acacia species (numerous Australian and African species contain DMT), and Desmanthus illinoensis (the bundleflower, native to North America). The near-universal presence of DMT in the plant kingdom — and its production in mammalian brains — has led researchers to speculate that it may serve a fundamental biological function not yet fully understood.
When smoked or vaporized (the most common modern route of administration), DMT produces an experience of extraordinary intensity and brevity. Within 15-30 seconds of inhalation, the ordinary perceptual world is rapidly replaced by an immersive visual landscape of geometric forms, fractal patterns, and hyperdimensional structures of astonishing complexity and apparent meaningfulness. Within 2-5 minutes, at sufficient doses (typically 25-60mg vaporized), many users report complete dissolution of the ordinary sense of self and physical surroundings, replaced by what is variously described as 'breaking through' into an apparently autonomous space populated by entities or presences that seem to possess independent intelligence and intentionality. The experience peaks within 3-5 minutes and resolves within 15-20 minutes, after which the user returns to baseline with remarkable rapidity — often reporting that the experience felt as though it lasted hours or was somehow outside of time altogether. This combination of extreme intensity with rapid onset and offset has led to DMT being called 'the businessman's trip,' though the characterization trivializes what many participants describe as the most profound experience of their lives.
The entity encounter phenomenon is the most scientifically provocative and least explained aspect of DMT experiences. In Rick Strassman's clinical studies at the University of New Mexico (1990-1995) — the first federally approved psychedelic research in the United States in over 20 years — approximately 50% of participants receiving high-dose intravenous DMT reported encounters with apparently autonomous beings. These entities were described in remarkably consistent terms across participants: insectoid or mechanical in appearance, telepathic in communication, curious about or delighted by the participant's arrival, and engaged in complex activities (manufacturing, teaching, performing, demonstrating) in spaces that seemed to have their own architecture and physics. Similar entity encounters are reported across cultures and historical periods — from the 'machine elves' described by Terence McKenna to the spirit beings described by Amazonian ayahuasqueros to the 'jeweled self-dribbling basketballs' and 'self-transforming elf machines' that recur in experience reports.
The question of DMT's endogenous production in the human body has been the subject of decades of speculation and, more recently, direct experimental investigation. The hypothesis — most prominently advanced by Rick Strassman in his 2001 book DMT: The Spirit Molecule — proposes that DMT is produced endogenously in the human brain, potentially by the pineal gland, and that endogenous DMT release may be involved in dreaming, near-death experiences, mystical states, birth, and death. The evidence for endogenous DMT production has evolved considerably. Barker et al. (2012) detected DMT in the pineal gland microdialysate of live rats using liquid chromatography-mass spectrometry, confirming that the mammalian brain produces DMT. Dean et al. (2019) demonstrated that the enzymes required for DMT biosynthesis (INMT — indolethylamine-N-methyltransferase, and AADC — aromatic amino acid decarboxylase) are present in human brain tissue, including but not limited to the pineal gland. However, the concentrations detected in brain tissue are very low, and whether endogenous DMT reaches psychoactive concentrations under any natural conditions remains unresolved.
Methodology
Pharmacokinetics of smoked/IV DMT. When administered intravenously (as in Strassman's studies), DMT reaches peak plasma concentrations within 2 minutes, produces peak subjective effects within 3-5 minutes, and is eliminated with a plasma half-life of approximately 15 minutes. The rapid onset and offset reflect DMT's rapid distribution to brain tissue and equally rapid metabolism by MAO-A and other enzymes. When smoked/vaporized, the pharmacokinetic profile is similar but slightly more variable depending on inhalation technique. The dose-response relationship is steep: there is relatively little difference between a sub-threshold and a breakthrough dose, meaning small changes in the amount consumed (5-10mg) can dramatically change the qualitative character of the experience.
5-HT2A receptor agonism and beyond. Like other classical psychedelics, DMT acts primarily as an agonist at serotonin 5-HT2A receptors. However, DMT's receptor pharmacology is broader than that of psilocybin or LSD. DMT also activates 5-HT2C receptors, 5-HT1A receptors (which may contribute to the peaceful, accepting quality of the experience), sigma-1 receptors (which are involved in cellular stress responses, neuroprotection, and the regulation of ion channels), and trace amine-associated receptors (TAAR1). The sigma-1 receptor interaction is particularly interesting because it is unique among classical psychedelics — psilocybin and LSD have negligible sigma-1 activity — and has led some researchers (notably Frecska et al., 2013) to propose that DMT may function as an endogenous sigma-1 agonist with neuroprotective and anti-inflammatory roles independent of its psychedelic effects.
Biosynthesis pathway. The endogenous synthesis of DMT from the common amino acid tryptophan requires two enzymatic steps: (1) decarboxylation of tryptophan to tryptamine by aromatic amino acid decarboxylase (AADC), and (2) double N-methylation of tryptamine by indolethylamine-N-methyltransferase (INMT), first to N-methyltryptamine (NMT) and then to N,N-dimethyltryptamine (DMT). Both enzymes are expressed in the human brain (Dean et al., 2019), establishing the biochemical feasibility of in situ brain DMT production. The regulation of this pathway — what controls the rate of endogenous DMT production, whether it can be upregulated under specific conditions, and what function it serves — remains largely unknown.
EEG and neuroimaging protocols. Modern DMT research employs high-density EEG (64-256 channels), fMRI, and MEG to characterize the neural correlates of the DMT state. The challenge is unique: the experience is so intense and disorienting that participants must be carefully prepared and supported while lying in a scanner or wearing electrode caps. Timmermann et al. (2019) developed a protocol using slow IV infusion (over 30 seconds rather than Strassman's rapid bolus) to allow EEG recording during the transition into and out of the DMT state, capturing the moment-by-moment evolution of brain electrical activity as consciousness shifts from ordinary to breakthrough states.
Phenomenological analysis methods. Quantifying the DMT experience requires specialized instruments. The Hallucinogen Rating Scale (HRS, developed by Strassman), the Altered States of Consciousness questionnaire (ASC, Dittrich), the Mystical Experience Questionnaire (MEQ30, MacLean and Griffiths), and the Entity Encounter Scale (Davis et al., 2020) have all been used. Large-scale survey studies (Davis et al., 2020) and qualitative analysis using interpretive phenomenological analysis (IPA) and grounded theory have been employed to characterize the entity encounter phenomenon.
Evidence
Rick Strassman's clinical studies (1990-1995). The foundational modern research on DMT was conducted by psychiatrist Rick Strassman at the University of New Mexico. Over five years, Strassman administered approximately 400 doses of intravenous DMT to 60 volunteers in the first federally approved psychedelic research in the United States since the 1970s. The studies used a double-blind, placebo-controlled design with multiple dose levels (0.05, 0.1, 0.2, 0.4 mg/kg) and characterized DMT's pharmacological, physiological, and subjective effects with unprecedented precision. Key findings: DMT produced dose-dependent increases in heart rate, blood pressure, pupil diameter, rectal temperature, and plasma cortisol, prolactin, growth hormone, and beta-endorphin. Subjective effects were fully developed within 2 minutes of injection, peaked at 3-5 minutes, and resolved within 30 minutes. At the highest dose (0.4 mg/kg), participants consistently reported complete dissolution of the external environment, immersion in vivid visual spaces, encounters with perceived entities, and experiences described as 'more real than real.' Strassman published these findings in peer-reviewed journals (Psychopharmacology, Archives of General Psychiatry) and in his landmark book DMT: The Spirit Molecule (2001).
Endogenous DMT detection. The question of whether the body produces DMT has been progressively answered through increasingly sensitive analytical techniques. Franzen and Gross (1965) first detected DMT in human blood. Barker et al. (2012) used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to detect DMT in the pineal gland microdialysate of live rats — confirming production in the brain rather than mere presence in blood from peripheral sources. Dean et al. (2019) demonstrated that the genes encoding the two enzymes required for DMT biosynthesis from tryptophan (AADC and INMT) are expressed in multiple regions of the human brain, including the cortex, choroid plexus, and pineal gland — distributed across the brain rather than concentrated in the pineal as Strassman had hypothesized. Critically, Dean et al. also showed that human cerebral cortex can produce DMT from tryptophan in vitro, establishing the brain's biochemical capacity for DMT synthesis. The remaining question — whether endogenous DMT ever reaches psychoactive concentrations in the living human brain — has not been answered, primarily because measuring real-time DMT levels in the human brain during states of interest (dreaming, dying, mystical experience) is not yet technically feasible.
DMT in the dying brain. Borjigin et al. (2019, published in Scientific Reports) detected a significant surge of DMT levels in the visual cortex of dying rats during cardiac arrest. This finding is the strongest evidence to date that endogenous DMT may play a role in near-death experiences, though extrapolation from rats to humans requires caution. The study measured a 4-7 fold increase in cortical DMT levels at cardiac arrest, reaching concentrations that, while still below estimated psychoactive thresholds for exogenous administration, represent the highest endogenous levels observed and may be sufficient to affect neural processing in the context of a globally disrupted brain.
Neuroimaging studies. Timmermann et al. (2019, published in Scientific Reports) conducted the first EEG study of intravenous DMT in humans under modern protocols at Imperial College London. The study found that DMT dramatically altered brain electrical activity: alpha oscillations (associated with relaxed wakefulness) collapsed, delta and theta oscillations (associated with dreaming and deep states) emerged despite participants being awake, and overall signal diversity (a measure of neural complexity) increased to levels exceeding waking consciousness. Remarkably, the EEG patterns during DMT were more similar to dreaming than to any other measured state of consciousness, supporting the hypothesis that DMT and dreaming may share underlying neural mechanisms. A subsequent study by Timmermann et al. (2023) using fMRI during extended-state DMT (continuous infusion) showed global increases in brain connectivity and a pattern of neural activity distinct from other psychedelics — increased rather than decreased global brain metabolism.
The DMT entity encounter survey. Davis et al. (2020, published in the Journal of Psychopharmacology) conducted the largest survey of DMT entity encounters to date — 2,561 respondents reporting on their most memorable entity encounter experience. Key findings: 72% of respondents received a message or prediction during the encounter; 78% reported that the entity continued to exist after the experience ended; 80% reported that the encounter altered their fundamental understanding of reality; 69% reported that the entity was conscious and intelligent; and the emotional valence was overwhelmingly positive (joy, trust, surprise, love). The experience was rated as more real than normal waking consciousness by a majority of respondents. Remarkably, among those who identified as atheist before the experience, 28% no longer identified as atheist afterward — one of the largest shifts in metaphysical belief documented in consciousness research.
Practices
Smoked/vaporized DMT. The most common modern method of DMT consumption involves vaporizing freebase DMT and inhaling the vapor. The freebase form (as distinct from DMT fumarate or other salt forms) is required because it vaporizes at a relatively low temperature (approximately 60-80 degrees Celsius). Users typically load 15-60mg of freebase DMT into a glass pipe, vaporizer, or similar device and inhale the vapor in 1-3 lung-fulls, holding each inhalation for as long as possible. At threshold doses (10-15mg), effects include enhanced visual perception, emotional shifts, and geometric closed-eye visuals. At moderate doses (20-30mg), visual effects become immersive and may include body sensation changes and mild ego softening. At 'breakthrough' doses (35-60mg), the external environment is entirely replaced by an immersive visionary space. The entire experience lasts 10-20 minutes, with full return to baseline within 30-45 minutes. The extreme rapidity of onset — from sober to full immersion in 15-60 seconds — is unlike any other psychedelic and can be disorienting or frightening without preparation.
Pharmahuasca and oral DMT. Pharmahuasca refers to the use of pharmaceutical-grade MAO inhibitors (typically harmine or harmaline capsules, or the pharmaceutical MAOI moclobemide) in combination with oral DMT to reproduce the pharmacology of ayahuasca without the traditional brew. This produces a longer experience (3-5 hours) with more gradual onset and a profile more similar to ayahuasca than smoked DMT. The oral route carries the same MAOI interaction risks as ayahuasca (serotonin syndrome with serotonergic medications, tyramine interaction with certain foods). Some researchers and practitioners prefer this approach because the extended duration allows for more therapeutic work and integration than the brief smoked experience.
Extended-state DMT (DMTx). Andrew Gallimore (a neurobiological pharmacologist) and Rick Strassman have proposed and published protocols for maintaining the DMT state for extended periods (30 minutes to several hours) using continuous intravenous infusion with target-controlled pharmacokinetic modeling. The rationale is that the brevity of smoked DMT prevents sustained exploration or systematic investigation of the 'DMT space' and its apparent inhabitants. Extended-state protocols would allow participants to spend meaningful time in the DMT state, conduct planned observations, and potentially interact with encountered entities in ways that could generate testable data about their nature. As of 2024, preliminary studies using this approach are underway at Imperial College London and elsewhere, though full results have not been published.
Ayahuasca as oral DMT delivery. The most established traditional practice involving DMT is the Amazonian ayahuasca ceremony, in which DMT from Psychotria viridis or Diplopterys cabrerana is made orally active through combination with MAO-inhibiting beta-carbolines from Banisteriopsis caapi. This practice has been documented for at least 1,000 years and is the context in which the vast majority of human DMT experiences in history have occurred. The ayahuasca context embeds the DMT experience within a ceremonial framework, a guiding curandero, icaros (healing songs), and a tradition of interpretation and integration that pure DMT consumption typically lacks.
5-MeO-DMT practices. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a related but pharmacologically distinct compound found in the venom of the Sonoran desert toad (Bufo alvarius/Incilius alvarius) and in several plant species. It produces a qualitatively different experience from N,N-DMT — less visual, more somatic and non-dual, often described as a white-out or dissolution into pure consciousness rather than entry into a populated visionary space. Traditional use of 5-MeO-DMT in toad venom ceremonies has been attributed to indigenous groups in the Sonoran Desert region, though the historical evidence is debated. Modern ceremonial use has expanded rapidly, raising both ethical concerns (toad conservation, cultural appropriation) and therapeutic interest (emerging evidence for efficacy in treatment-resistant depression and PTSD).
Risks & Considerations
Psychological overwhelm. DMT produces the most intense departure from ordinary consciousness of any known psychoactive substance, and the speed of onset — sober to full immersion in under 60 seconds — can be psychologically shattering for unprepared individuals. Unlike psilocybin or ayahuasca, which develop gradually and allow the user to acclimate, smoked DMT provides no adjustment period. Fear, panic, and the sensation of dying are reported by a significant minority of users, particularly at breakthrough doses. The intensity can produce lasting psychological disturbance in vulnerable individuals — though in Strassman's clinical studies, no participant experienced lasting adverse effects, and most described the experience as profoundly positive despite its intensity.
Interaction with existing mental health conditions. As with other serotonergic psychedelics, DMT poses risks for individuals with predisposition to psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I with psychotic features). The intense perceptual distortions and entity encounters could trigger or exacerbate psychotic symptoms. DMT should be avoided by individuals with these conditions or with first-degree family history of them.
Physical risks of smoked administration. Vaporizing and inhaling DMT carries respiratory risks: the harsh smoke or vapor can irritate airways, and holding deeply inhaled smoke for extended periods carries standard pulmonary risks. The rapid onset can cause users to lose motor control while holding a hot pipe, creating a burn risk. Some users experience brief loss of consciousness at breakthrough doses. MAOI-containing preparations (pharmahuasca, ayahuasca) carry serotonin syndrome risk when combined with serotonergic medications.
Ontological shock and integration challenges. The DMT experience can produce what might be called 'ontological shock' — a destabilization of fundamental assumptions about the nature of reality, the self, and the relationship between consciousness and the physical world. Encountering what feels like autonomous non-human intelligences in a space that feels 'more real than real' can be profoundly disorienting and difficult to integrate into a materialist worldview. Some individuals experience lasting existential confusion, depersonalization, or difficulty determining what is 'real.' Integration support — through therapy, community, or contemplative practice — is important but often unavailable to those using DMT outside of research or ceremonial contexts.
Unregulated production and purity concerns. DMT is a Schedule I controlled substance in the United States and most other countries. Users typically obtain it through illegal synthesis or extraction, with no quality control or purity verification. Contamination with synthesis byproducts, solvents, or other substances is a real risk. Dosing precision is difficult with improvised vaporization methods, and the steep dose-response curve means that small errors in measurement can dramatically alter the experience.
Significance
DMT occupies a unique position at the intersection of neuroscience, pharmacology, philosophy of mind, and the study of mystical and anomalous experiences. Its significance for consciousness research is multidimensional and, in several respects, unmatched by any other compound.
The endogenous production question is perhaps the most consequential. If the human brain produces a compound capable of generating the most intense alterations of consciousness known — a compound that reliably produces experiences of encountering apparently autonomous non-human intelligences — then our understanding of the brain's capacity to generate experience requires fundamental revision. The materialist model of consciousness assumes that all subjective experience is generated by and confined to patterns of neural activity. If the brain can endogenously produce experiences indistinguishable from encounters with external intelligences, this raises the question: how do we determine whether any perception is 'real' or 'generated'? The DMT experience does not resolve the question — it makes it more urgent and more interesting.
The entity encounter phenomenon challenges both materialist and spiritualist interpretations. From a materialist perspective, the consistency of entity encounters across individuals, cultures, and historical periods could reflect either shared neural architecture (the brain, when sufficiently perturbed by 5-HT2A agonism, generates a consistent pattern of 'perceived agency') or cultural transmission (people describe what they expect to see). From a non-materialist perspective, the consistency could indicate genuine contact with non-physical intelligences or dimensions of reality normally inaccessible to ordinary perception. The data does not definitively support either interpretation, and the intellectual honesty of the field requires holding both possibilities open. Andrew Gallimore and Rick Strassman have proposed experimental protocols for extended-state DMT experiences (using continuous intravenous infusion to maintain the DMT state for prolonged periods) specifically to investigate whether the 'entities' demonstrate properties — such as providing verifiable information unknown to the participant — that would distinguish genuine contact from neural confabulation.
DMT's relationship to dreaming and near-death experiences adds further layers. The phenomenological parallels between DMT experiences, lucid dreams, and NDEs — visual immersion, entity encounters, time distortion, emotional intensity, noetic quality, the sense of accessing a 'more real' reality — have led to the hypothesis that these may all involve the same underlying neurochemical process. If endogenous DMT release contributes to dreaming (a hypothesis supported by the presence of DMT-synthesizing enzymes in the choroid plexus and pineal gland, both of which are active during REM sleep) and to NDEs (a hypothesis supported by the detection of a DMT surge in the dying rat brain in a 2019 study by Borjigin et al.), then DMT may be a key molecule in the brain's own capacity to generate immersive, consensus-defying experiences — the capacity that every night, in dreams, creates entire worlds indistinguishable from waking reality.
For the broader field of consciousness studies, DMT serves as a limiting case — the most extreme deviation from ordinary consciousness that can be pharmacologically induced, returned from, and articulated. Understanding what happens during a DMT experience — at the level of neural activity, subjective report, and whatever ontological status the experience may hold — would illuminate the mechanisms by which consciousness constructs the world we call 'reality.' Whether DMT opens a door to another dimension or demonstrates the brain's staggering capacity for world-generation, the implications are equally profound.
Connections
Ayahuasca is the traditional delivery system for oral DMT, combining it with MAO-inhibiting beta-carbolines to enable absorption through the gut. The relationship between pure DMT and ayahuasca illuminates how molecular pharmacology, route of administration, duration, and cultural container all shape the qualitative character of a psychedelic experience built on the same molecule.
Psilocybin is pharmacologically closely related — psilocin (psilocybin's active metabolite) differs from DMT by a single hydroxyl group at the 4-position. Despite this structural similarity, the experiential profiles differ significantly: psilocybin produces a longer, more narrative, more emotionally textured experience, while DMT produces a brief, intensely visual, more otherworldly one. Comparing the two illuminates how subtle molecular differences translate into dramatically different conscious experiences.
Near-death experiences share extraordinary phenomenological overlap with DMT experiences — entity encounters, tunnel or passage experiences, life review, the sense of entering a domain more real than physical reality, and the lasting conviction that consciousness exists independently of the body. Borjigin's finding of elevated DMT in the dying rat brain provides a neurochemical basis for this connection, though it remains far from proven that endogenous DMT mediates human NDEs.
Lucid dreaming connects through the shared neuroscience of immersive conscious experience generated without external sensory input. The EEG signature of DMT (Timmermann et al., 2019) — particularly the emergence of delta and theta oscillations in awake participants — is more similar to dreaming than to any other measured state, supporting the hypothesis that DMT and dreaming may engage overlapping neural mechanisms.
Meditation neuroscience intersects through the question of whether contemplative practice can access states similar to those produced by DMT. Advanced meditators in Tibetan and Vedic traditions describe experiences of light, bliss, and encounter with subtle beings that parallel DMT phenomenology, and some researchers have proposed that deep meditation may upregulate endogenous DMT production — a hypothesis that remains untested.
The yogic concept of the ajna chakra (third eye), traditionally associated with the pineal gland region and with inner vision and spiritual perception, aligns remarkably with Strassman's hypothesis about pineal DMT production. Whether this represents genuine physiological insight preserved in contemplative tradition or coincidental mapping remains an open and fascinating question.
Further Reading
- Strassman, Rick. DMT: The Spirit Molecule. Park Street Press, 2001.
- Gallimore, Andrew. Alien Information Theory: Psychedelic Drug Technologies and the Cosmic Game. Strange Worlds Press, 2019.
- Strassman, Rick, Slawek Wojtowicz, Luis Eduardo Luna, and Ede Frecska. Inner Paths to Outer Space: Journeys to Alien Worlds Through Psychedelics and Other Spiritual Technologies. Park Street Press, 2008.
- McKenna, Terence. Food of the Gods: The Search for the Original Tree of Knowledge. Bantam Books, 1992.
- Timmermann, Christopher, et al. 'Neural Correlates of the DMT Experience Assessed with Multivariate EEG.' Scientific Reports 9, 2019.
- Dean, Jon G., et al. 'Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain.' Scientific Reports 9, 2019.
- Davis, Alan K., et al. 'Survey of Entity Encounter Experiences Occasioned by Inhaled N,N-Dimethyltryptamine.' Journal of Psychopharmacology 34(9), 2020.
- Barker, Steven A., et al. 'LC/MS/MS Analysis of the Endogenous Dimethyltryptamine Hallucinogens, Their Precursors, and Major Metabolites in Rat Pineal Gland Microdialysate.' Biomedical Chromatography 27(12), 2013.
- Borjigin, Jimo, et al. 'Surge of Neurophysiological Coherence and Connectivity in the Dying Brain.' Proceedings of the National Academy of Sciences 110(35), 2013.
- Frecska, Ede, Attila Szabo, Michael J. Winkelman, Luis Eduardo Luna, and Dennis J. McKenna. 'A Possibly Sigma-1 Receptor Mediated Role of Dimethyltryptamine in Tissue Protection, Regeneration, and Immunity.' Journal of Neural Transmission 120(9), 2013.
Frequently Asked Questions
Does the human brain actually produce DMT? What is the current evidence?
Yes, the mammalian brain does produce DMT, though the full picture is still emerging. Barker et al. (2012) detected DMT in the pineal gland microdialysate of live rats. Dean et al. (2019) demonstrated that the two enzymes required for DMT biosynthesis (AADC and INMT) are expressed in multiple regions of the human brain, including cortex, choroid plexus, and pineal gland, and showed that human cortical tissue can synthesize DMT from tryptophan in vitro. What remains unknown is whether the brain ever produces DMT at psychoactive concentrations under natural conditions — during dreaming, near-death states, meditation, or birth. The detected concentrations have been very low, but the dying rat brain shows a significant surge (Borjigin et al., 2019), suggesting that extreme states may trigger higher production. Current technology cannot measure real-time DMT levels in the living human brain during these states, so the question remains open.
What are the 'entities' that people encounter on DMT, and are they real?
Approximately 50% of people who take breakthrough doses of DMT report encounters with apparently autonomous beings — described variously as insectoid, mechanical, angelic, or clown-like, typically perceived as intelligent, intentional, and aware of the user's presence. These encounters are remarkably consistent across cultures, individuals, and historical periods. The ontological status of these entities is genuinely unknown. Materialist explanations propose that they are generated by the brain's agency-detection systems operating in overdrive — the same circuits that evolved to detect predators and social partners, activated by 5-HT2A receptor perturbation. Non-materialist interpretations suggest genuine contact with autonomous intelligences existing in dimensions normally inaccessible to human perception. Neither interpretation has been definitively supported or refuted. Extended-state DMT research protocols (Gallimore and Strassman) are being designed specifically to test whether entities can provide verifiable information unknown to the participant — which would distinguish genuine contact from neural confabulation.
How is DMT different from ayahuasca if they contain the same molecule?
The molecular payload overlaps but the experiences differ substantially. Smoked or injected DMT produces a 10-20 minute experience of extreme intensity with near-instantaneous onset — often described as being 'launched' into a completely alien perceptual space. Ayahuasca produces a 4-6 hour experience with gradual onset, involving not only DMT but also psychoactive beta-carboline alkaloids from the Banisteriopsis caapi vine that contribute meditative depth, emotional processing, and physical purging. The ayahuasca experience tends to be more narrative, more emotionally textured, and more amenable to therapeutic processing. The ceremonial container — the curandero, the icaros, the communal setting — also shapes the experience in ways pure DMT lacks. Indigenous practitioners consider the vine, not the DMT, to be the real medicine. Pharmacologically, the key difference is that ayahuasca's MAO inhibitors allow oral DMT absorption and slow its metabolism, fundamentally changing the time course and quality of the experience.
Is DMT connected to near-death experiences? What does the evidence show?
The connection is suggested by multiple lines of evidence but not proven. The phenomenological overlap is striking: both DMT experiences and NDEs involve tunnel or passage experiences, encounters with non-physical beings, the sense of entering a domain more real than physical reality, feelings of cosmic love and understanding, and lasting shifts in beliefs about consciousness and death. Borjigin et al. (2019) demonstrated a significant surge of DMT in the dying rat brain during cardiac arrest, providing direct evidence that the brain produces more DMT during the dying process. Dean et al. (2019) showed that the enzymes for DMT biosynthesis are distributed across the human brain, not just the pineal gland. However, the detected DMT concentrations remain below estimated psychoactive thresholds, and no one has measured DMT levels in a dying human brain. The hypothesis is plausible, has preliminary evidence, but cannot be called established. It is also possible that NDEs involve mechanisms beyond or alongside DMT release.